Diabetes and Pregnancy—An Endocrine Society Clinical Practice Guideline Publication Note Free

The recommendations contained in clinical practice guidelines reflect the state of the science at the time of writing. Each guideline can be thought of as providing a “snap shot” of best clinical practice at a particular point in time. Consequently, it is the nature of guideline recommendations to become less current as evidence develops and changes. In some specialties this aging process may happen soon after publication and, in others, it may take years. Guideline readers should always be aware of the potential for guidelines to age, particularly those that are more than 5 years old.

There are a number of recommendations in the Endocrine Society’s Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guide, by Blumer I, Hadar E, Hadden DR, Jovanovič L, Mestman JH, Murad MH, and Yogev Y, published in 2013, which warrant reevaluation in the light of new data. Examples are recommendations on noninsulin antihyperglycemic medications for the treatment of gestational diabetes, use of continuous glucose monitoring in the management of pregestational diabetes, the use of anti–vascular endothelial growth factor therapy in the context of planned or current pregnancy, and the use of aspirin to lower the risk of preeclampsia in women with pregestational diabetes.

The Endocrine Society has begun discussions on how best to update its older guidelines. A decision is expected by the end of 2018 and the Diabetes and Pregnancy guideline will be part of this review.

Acknowledgments

Disclosure Summary: The author has nothing to disclose.